Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 0.68 |
| ▸ | EGFR | P00533 | 8/20 | 0.68 |
| ▸ | AURKA | O14965 | 1/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3574994 | 0.85 | KDR (0.68) | KDREGFRAURKAAURKB | |
| SCHEMBL3528866 | 0.83 | EGFR (0.67) | KDREGFR | |
| SCHEMBL17780943 | 0.81 | KDR (0.64) | KDREGFR | |
| SCHEMBL31067608 | 0.79 | KDR (0.85) | KDREGFRAURKAAURKB | |
| Hydrochloric Acid SCHEMBL3528901 | 0.79 | EGFR (0.74) | KDREGFRAURKAAURKB | |
| SCHEMBL6161811 | 0.78 | HDAC3 (0.62) | KDREGFR | |
| SCHEMBL6163655 | 0.78 | HDAC3 (0.62) | KDREGFR | |
| SCHEMBL3529674 | 0.78 | AURKB (0.74) | KDREGFRAURKAAURKB | |
| SCHEMBL6163408 | 0.78 | HDAC3 (0.57) | KDREGFR | |
| SCHEMBL6163422 | 0.78 | HDAC3 (0.57) | KDREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709479-B1 | Quinazoline derivatives and their use as pharmaceuticals | ASTRAZENECA (SE) | 2010-05-04 | — | — | US | disclosed |
| EP-1218354-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | AstraZeneca AB (SE) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001021596-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2001-03-29 | — | — | WO | disclosed |